Studies of Populations Exposed to Therapeutic Medical Radiation and Other Agents

REB研究人员使用以下方法评估所有癌症后多种癌症的风险： 监测流行病学和最终结果计划癌症登记数据库，包括更多 从1973年到2008年诊断出的癌症幸存者超过200万。有趣的发现， 2006年多个主要专论已通过评价风险的个别研究进行了随访 与放疗和化疗有关的第二种癌症。特别感兴趣的研究 包括乳腺癌、霍奇金淋巴瘤、非霍奇金淋巴瘤、视网膜母细胞瘤 和儿童癌症。2012年，第二种癌症比例的首次估计与 放射治疗发表了。妇科良性疾病放射治疗后的癌症 - 良性妇科疾病放射治疗后癌症死亡率的队列研究 近15,000名妇女的个人辐射剂量数据正在更新，以评估固体 肿瘤和白血病风险。结果已于2012年提交出版。儿童癌症 生存者研究-在一个14,000名5年的儿童癌症生存者队列中，我们进行了 乳腺癌、甲状腺癌、唾液腺癌的巢式病例对照研究 腺体、骨、软组织和皮肤，以评估辐射与 化疗和这些癌症的风险。一项新的发现是，甲状腺癌的风险 与暴露于辐射较少的患者中既往接受烷化剂治疗相关 超过20戈伊。第二次乳腺癌与既往癌症关系的新分析 治疗和潜在的效果调节剂已经启动。CCSS也是一个独特的 资源和一个难得的机会，在其中检查基因辐射的潜力 互动特别值得注意的是生物标本的可用性，高质量 关于放射和化学疗法剂量的信息，以及暴露于放射性物质的年轻年龄， 队列。我们目前正在进行一个基因组范围内的关联研究，

REB investigators evaluate the risks of multiple cancers following all cancers using the Surveillance Epidemiology and End Results Program cancer registry database including more than 2 million cancer survivors diagnosed from 1973 to 2008. Interesting findings from the 2006 Multiple Primary Monograph have been followed up with individual studies evaluating risk of radiation-related and chemotherapy-related second cancers. Particular studies of interest include of survivors of breast cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, retinoblastoma, and childhood cancers. In 2012 the first estimates of the proportion of second cancers related to radiotherapy were published. Cancer Following Radiotherapy for Benign Gynecologic Disorders - Cancer mortality following radiation treatment for benign gynecologic conditions in a cohort of nearly 15,000 women with individual radiation dose data is being updated to evaluate solid tumor and leukemia risk. Results were submitted for publication in 2012. Childhood Cancer Survivor Study - In a cohort of 14,000 5-year survivors of childhood cancer we performed nested case-control studies of second primary cancers of the breast, thyroid gland, salivary gland, bone, soft tissue and skin to evaluate the relationship between radiation and chemotherapy and risk of these cancers. A novel finding was that thyroid cancer risk was related to prior treatment with alkylating agents among patients exposed to radiation less than 20 Gy to the thyroid. New analyses of second breast cancers in relation to prior cancer treatment and potential effect modifiers has been initiated. The CCSS also is a unique resource and a rare opportunity in which to examine the potential for gene-radiation interaction. Particularly noteworthy are the availability of biospecimens, high quality information on doses of radiation and chemotherapy, and the young age at exposure of the cohort. We are currently performing a genome wide association study of subsequent ne